Alnylam® Pharmaceuticals

FDA Approves Patisiran Infusion for Hereditary Transthyretin-Mediated Amyloidosis

The FDA announced that it has approved patisiran infusion for the treatment of patients with peripheral nerve disease caused by hereditary transthyretin-mediated…